COMMUNIQUÉS West-GlobeNewswire

Les résultats financiers du premier trimestre 2019 de Emerald Health Therapeutics démontrent une croissance continue des ventes
02/06/2019
Les ventes de Emerald augmentent de 131 % d'un trimestre à l'autre VANCOUVER, Colombie-Britannique, 02 juin 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH; OTCQX: EMHTF) a présenté [...]
G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2019
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical- [...]
Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
01/06/2019
--Evaluation of biomarkers for patient selection to be incorporated into expanded development program-- HAMPTON, N.J., June 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented results [...]
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
01/06/2019
24% overall response rate in ITT population Responses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated BERKELEY, Calif., June 01, 2019 (GLOBE [...]
Merus annonce ses résultats financiers pour le premier trimestre 2019 et fait le point sur ses activités
01/06/2019
UTRECHT, Pays-Bas, 01 juin 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », « nous », « notre » ou la « Société »), société spécialisée en immuno-oncologie de stade clinique qui développe Biclonics®, un [...]
XBiotech annonce la tarification de son offre publique pour l'émission d'actions ordinaires
01/06/2019
AUSTIN, Texas, 01 juin 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui la tarification d'une offre publique de souscription portant sur 4 848 485 de ses actions ordinaires à un prix public [...]
Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
01/06/2019
Trial in Progress Poster to be Presented Today at the 2019 American Society of Clinical Oncology Annual Meeting WOBURN, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology [...]
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
01/06/2019
Data provides further evidence that GoCAR-T ® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received lymphodepletion with [...]
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
01/06/2019
Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq [...]
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
01/06/2019
- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- CytomX [...]
BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting
01/06/2019
CAMBRIDGE, Mass. and BEIJING, China, June 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting
01/06/2019
Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate ( [...]
Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2019
SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
01/06/2019
Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of Viaskin ® Peanut DBV Technologies (Euronext: DBV – [...]
DBV Technologies : présentation de données sur l’immunothérapie épicutanée au congrès du EAACI 2019
01/06/2019
Montrouge, France, le 1 juin (14 h 00 CET) 2019 DBV Technologies : présentation de données sur l’immunothérapie épicutanée au congrès du EAACI 2019 Les données présentées mettent en évidence les avantages potentiels à [...]
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
01/06/2019
Conquer Cancer Foundation/ Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania Lugano, Switzerland, June [...]
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
01/06/2019
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for women who received Kisqali [...]
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting
01/06/2019
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson Cancer Center and Sarah [...]
Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies
01/06/2019
PRESS RELEASE : 1 June 2019, 07:00 CEST Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies Mechelen, Belgium, 1 June 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an [...]

Pages